АSSOCIATION BETWEEN OXIDATIVE-ANTIOXIDANT MODIFICATIONS OF LOW-DENSITY LIPOPROTEINS AND CORONARY HEART DISEASE IN A MALE POPULATION OF NOVOSIBIRSK

Aim. To investigate the association between potentially atherogenic oxidativeantioxidant modifications of low-density lipoproteins (LDL) and coronary heart disease (CHD) in a male population. 

Material and methods. A population-based survey included 1024 male residents ofNovosibirskCity, aged 47–73 years. The participants underwent a questionnaire survey, a standard cardiologic survey, anthropometry, blood pressure measurement, and electrocardiography. “Definite CHD” (Functional Class II–IV stable effort angina) was registered in 223 men (21,8%), according to validated epidemiologic, clinical, and functional criteria. Blood biochemistry analyses focused on the levels of total cholesterol (TCH), triglycerides (TG), high-density lipoprotein cholesterol (HDL–CH), high-sensitivity C-reactive protein (hsCRP), glucose, baseline levels of lipid peroxidation (LPO) products and fat-soluble antioxidants (alpha-tocopherol, retinol, beta-carotene, and xanthines) in LDL, LDL oxidation resistance in vitro, and an concentration of autoantibodies to oxidised LDL (oxLDL). 

Results. There were positive correlations and independent associations between the oxidative LDL modifications, in particular between reduced LDL oxidation resistance and CHD. On the other hand, there were negative correlations between the antioxidant LDL modifications (such as reduced alpha-tocopherol levels in LDL) and CHD. The prevalence of CHD was higher in participants with baseline levels of LPO products in LDL >0,8 nM MDA/mg LDL protein and with reduced LDL oxidation resistance (baseline levels >5,4 nM MDA/mg LDL protein vs. levels >13,2 nM MDA/mg LDL protein at later stages of LDL oxidation). However, the prevalence of CHD was lower in individuals with LDL levels of alpha-tocopherol >1,06 mg/mg LDL protein. 

Conclusion. These findings agree with the previously obtained data on the key role of oxidative LDL modifications in the pathogenesis of atherosclerosis and CHD.

1. Osterud B, Bjorklid E. Role monocytes in atherogenesis. Physiol. Rev., 2003; 83: 1069–113.

2. Williams KJ, Fisher EA. Oxidation, lipoproteins and atherosclerosis. Curr. Opin. in Clin. Nutr. Care, 2005; 8:139–46.

3. Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J. Lipid Res., 2009; Suppl.: S376-S81.

4. Stocker R, Keaney JF. New insights on oxidative stress in the artery wall. J. Thromb. Haemost., 2005; 3 (8):1825–34.

5. Menschikova EB, Lankin VZ, Zenkov NK, et al. Oxidative stress. Prooxidants and antioxidants. Moscow: Word, 2006, 560 p. Russian (Меньщикова Е. Б., Ланкин В. З., Зенков Н. К. и др. Окислительный стресс. Прооксиданты и антиоксиданты. Москва: Слово, 2006, 560 с.).

6. De Rosa S, Cirillo P, Paglia A, et al. Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? Curr. Vasc. Pharmacol., 2010; 8 (2):259–75.

7. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr. Opin. Lipidol., 2009; 20 (5):363–9.

8. Esterbauer H, Jurgens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Current Opinion in Lipidology, 1993; 4:114–24.

9. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin. Chim. Acta, 2010; 411 (23–24):1875–82.

10. Ragino YuI, Voevoda MI, Dushkin MI, et al. Application of new biochemical methods for evaluation of oxidative-antioxidative potential of low density lipoproteins. Clinical laboratorial diagnostic, 2005; 4:11–5. Russian (Рагино Ю. И., Воевода М. И., Душкин М. И. и др. Применение новых биохимических способов для оценки окислительно-антиоксидантного потенциала липопротеинов низкой плотности.

11. Клиническая лабораторная диагностика, 2005; 4:11–5).

12. Saremi A, Arora R. Vitamin E and cardiovascular disease. Am. J. Ther., 2010; 17 (3): e56-е 65.

13. Ragino YuI, Krivchun AS, Ivanova MV et al. Oxidative-antioxidants modifications of low density lipoproteins and their associations with some atherosclerosis risk factors in men population of Novosibirsk. Russian journal of cardiology, 2012; 3:56–62. Russian (Рагино Ю. И., Кривчун А. С., Иванова М. В. и др. Окислительно-антиоксидантные изменения липопротеинов низкой плотности и их ассоциации с некоторыми факторами риска атеросклероза в популяции мужчин Новосибирска. Российский кардиологический журнал, 2012; 3:56–62).

14. Mitra S, Deshmukh A, Sachdeva R, et al. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am. J. Med. Sci., 2011; 342 (2):135–42.